Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP: AWKNF )

0.0650 -0.0147 (-18.44%)
Streaming Delayed Price Updated: 3:11 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Awakn Life Sciences Corp

< Previous 1 2 3 4 5 Next >
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62 
Via Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17 
Via Benzinga
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry. 
Via Talk Markets
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. 
Via Talk Markets
Awakn Life Sciences: Wake Up To The Huge Potential
The private global addiction treatment industry is currently valued at US$17.5 billion per year and forecast to increase to US$31.5 billion per year by 2027. 
Via Talk Markets
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
GAINERS: Field Trip Health (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 21, 2022
GAINERS: GH Research (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
GAINERS: Small Pharma (OTC: 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS: Cybin (AMEX: 
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: 
Via Benzinga
Ketamine Therapy Shows Potential In Treatment Of Alcohol Use Disorder, New Study Finds
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:AWKNF) publis... 
Via Benzinga
The Year In Review For Psychedelic Drug Stocks: 2021
2021 was two different 
Via Talk Markets
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
AWKNF: A Psychedelic's Stock Exhibiting Recent Price Appreciation
Awakn Health Sciences Corp's trading pattern over the past 10-day time span is an egregious example of a psychedelic stock that has exhibited recent price appreciation coupled with a surge in average... 
Via Talk Markets
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
New Options to Treat Alcohol Use Disorder
New Options to Treat Alcohol Use Disorder 
Via News Direct
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. 
Via Talk Markets
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways reported 
Via Talk Markets
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
The Week In Psychedelics: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
The Week In Psychedelics 
Via Benzinga
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148%
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD. 
Via Talk Markets
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
The Week In Psychedelics: 
Via Benzinga
Is Ketamine A Psychedelic? Depends On Who You Ask
Ketamine, an FDA-approved anesthetic drug, has recently become the star of the psychedelic medicine movement. As p... 
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Cannabis Drug Stocks Have Mirrored Performance Of Psychedelic Drug Stocks To Date In September
Which index has outperformed so far in September, the Pure-Play Marijuana-Based Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index? 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares 
Via Benzinga
Cannabis And Psychedelic Drug Stock Performances Were Mixed Last Week
The performance of the psychedelic-focused index components substantially outshone the weed stocks. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.